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Accumulation of Ab peptide fragments of the APP
protein and neurofibrillary tangles of the microtu-
bule-associated protein tau are the cellular hallmarks
of Alzheimer’s disease (AD). To investigate the rela-
tionship between APP metabolism and tau protein
levels and phosphorylation, we studied human-
stem-cell-derived forebrain neurons with genetic
forms of AD, all of which increase the release of path-
ogenic Ab peptides. We identified marked increases
in intracellular tau in genetic forms of AD that either
mutated APP or increased its dosage, suggesting
that APP metabolism is coupled to changes in tau
proteostasis. Manipulating APP metabolism by
b-secretase and g-secretase inhibition, as well as
g-secretase modulation, results in specific increases
and decreases in tau protein levels. These data
demonstrate that APPmetabolism regulates tau pro-
teostasis and suggest that the relationship between
APP processing and tau is not mediated solely
through extracellular Ab signaling to neurons.
INTRODUCTION
Accumulation of Ab peptide fragments of the APP protein and
neurofibrillary tangles of the microtubule-associated protein
tau are the cellular hallmarks of Alzheimer’s disease (AD). How-
ever, the molecular mechanisms linking APP metabolism;
extracellular Ab peptides; and changes in tau expression,
phosphorylation, and cellular localization are currently unclear.
Understanding of the genetics underlying monogenic familial
Alzheimer’s disease (fAD) has provided several insights into
disease pathogenesis (Blennow et al., 2006). The majority of
known fAD mutations are autosomal dominant and affect
APP or the catalytic components of the g-secretase APP-pro-
cessing complex, presenilin (PSEN) 1 and 2 (Bertram and
Tanzi, 2008). Early onset AD also occurs in individuals withincreased APP gene dosage due either to trisomy of chromo-
some 21 (Ts21) or duplication of the APP locus (APP (dup))
(Rovelet-Lecrux et al., 2006). The identification of the mutations
involved in fAD, the discovery of Ab42 as the primary compo-
nent of cerebrovascular amyloid (Glenner and Wong, 1984a)
and amyloid plaques (Masters et al., 1985) in late-onset spo-
radic AD, and the identification of the same peptide in amyloid
plaques in Down syndrome (Glenner and Wong, 1984b) led to
the development of the amyloid hypothesis for AD (Hardy and
Allsop, 1991).
The amyloid hypothesis postulates that accumulation of Ab42
is central to AD initiation and subsequently leads to changes in
neuronal function, tau pathology, and ultimately cell death
(Hardy and Allsop, 1991). Increased production of aggregation-
prone Ab monomers during AD initiation results in the formation
of soluble extracellular oligomers that are proposed to signal via
several different specific cell surface receptors or perturb mem-
brane integrity in a non-specific manner, resulting in neuronal
dysfunction (Benilova et al., 2012). Changes in APP processing
and the generation of intracellular APP fragments have also
been proposed to be involved in AD pathogenesis (Pimplikar
et al., 2010). The b-secretase-generated C-terminal fragment
of APP, referred to as b-CTF or C99, has been shown to be toxic
in cultured cells (Yankner et al., 1989) and cause neurodegener-
ation and defects in synaptic plasticity in transgenic mouse
models (Lauritzen et al., 2012). Similarly, cleavage of APP-C99
by g-secretase releases the APP intracellular domain (AICD),
which is proposed to contribute to neurodegeneration (Pimplikar
et al., 2010).
We and others have previously shown that neurons generated
from induced pluripotent stem cells (iPSCs) from genetic forms
of AD recapitulate aspects of the disease, including increased
Ab peptide production in Down syndrome (Shi et al., 2012a)
and APP duplication (Israel et al., 2012). Altered Ab40:42 ratios
have also been observed in PSEN1 and APP mutant neurons
(Muratore et al., 2014; Yagi et al., 2011). Here, we investigate
the relationship between APP processing and tau protein levels
and phosphorylation by analysis of iPSC-derived cortical neu-
rons with different genetic forms of AD and pharmacological
manipulation of b-secretase and g-secretase.Cell Reports 11, 689–696, May 5, 2015 ª2015 The Authors 689
Figure 1. Altered APP Processing and Ab Peptide Production in Stem Cell Models of Genetic Forms of Alzheimer’s Disease
(A–C) Representative immunohistochemistry of neurons (b3-tubulin positive, blue) generated from familial Alzheimer’s disease (fAD) (PSEN1 intron 4, Y115C, and
APP V717I) iPSCs, expressing transcription factors restricted to layer 6 (Tbr1, red) or layer 5 (CTIP2, green) cortical projection neurons.
(D) 3D nature of stem-cell-derived cortical cultures. Cultures cleared by passive CLARITY and immunostained for neurons (tau, red) and nuclei (DAPI, blue).
Single-plane XY, XZ, and YZ (right, top, and left panels, respectively) projections of control neurons 100 days post-induction. The scale bar represents 100 mm.
(E) Generation of Ab peptides. APP is first cleaved by b-secretase to generate membrane-bound APP-C99. This is followed by the initial g-secretase cleavage of
APP-C99, termed ε-cleavage, to generate Ab peptides of either 48 or 49 amino acids. Ab peptides are then subject to sequential g-secretase carboxypeptidase
cleavages, leading to extracellular release of Ab42, 40 and 38.
(F) Neurons with three different PSEN1mutations generate equivalent amounts of total extracellular Ab peptides over 40 days in culture as three different healthy
control lines. APP V717I neurons also do not significantly alter the production of total Ab peptides compared to controls. This is in contrast with APP (dup)
neurons, which significantly increase Ab production. Error bars, SD; n = 3 cultures for each genotype; **p < 0.01.
(G) PSEN1 and APP V717I mutant neurons have significantly reduced Ab40:Ab42 ratios compared with both control and APP (dup) neurons at all time points
studied, reflecting a relative increase in the generation of Ab42. Error bars, SEM; **p < 0.01.
(legend continued on next page)
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RESULTS
Distinct Genetic Forms of Alzheimer’s Disease All
Increase Ab42 Generation
APP processing and generation of Ab peptides in different ge-
netic forms of AD was studied by generating cortical excitatory
neurons from patient iPSCs (Shi et al., 2012c) harboring
PSEN1mutations (Y115C,M146I, and intron 4), anAPPmutation
(V717I), and APP duplication (APPdup) (Israel et al., 2012; Figures
1A–1C and S1). Over 3 months, neurons generated from mono-
layers of cortical progenitor cells formed dense 3D, electrically
active neural networks that spanned >200 mm in thickness (Fig-
ure 1D; Movies S1 and S2).
Production of extracellular Ab peptides by neurons of each ge-
notype was compared with that of three independent controls
over the course of 90 days in culture. At all time points, PSEN1
and APP V717I neurons produced similar extracellular concen-
trations of the sum of Ab38, 40, and 42 peptides as healthy con-
trol neurons (Figures 1E and 1F). However, these mutants
decreased the ratio of Ab40:Ab42 at each point assessed (Fig-
ures 1F and 1G), reflecting an absolute and relative increase in
Ab42 production compared with controls. In contrast with the
other genotypes, APPdup neurons greatly overproduce Ab pep-
tides over time, in line with increased substrate dosage (Fig-
ure 1F), as previously found for Ts21 neurons (Shi et al.,
2012a). Overproduction of Ab peptides in APPdup neurons did
not alter the relative amounts of Ab40 and Ab42 (Figures 1G
and 1H), indicating that Ab generation is limited by APP availabil-
ity, rather than b- and g-secretase capacity.
Comparing relative amounts of Ab40 with the sum of Ab38 and
Ab42 peptides enables inference about the initial ε-cleavage of
APP-C99 by g-secretase to either Ab48 or Ab49 that are then
processed in largely separate pathways (Figure 1E; Cha´vez-Gu-
tie´rrez et al., 2012). APP V717I neurons exhibited a significant
decrease in the Ab40:Ab38+Ab42 ratio, which was not observed
in APP dosage models or PSEN1mutants (Figure 1I), consistent
with the V717I mutation biasing the initial ε-cleavage of APP to
Ab48, which is processed to both Ab42 and Ab38 (Figure 1E).
Multiple PSEN1mutations resulted in a decreased Ab38:Ab42
ratio (Figure 1J), consistent with a hypomorphic loss of g-secre-
tase function (Cha´vez-Gutie´rrez et al., 2012). In support of this,
PSEN1 mutants significantly increased the release of Ab14,
Ab15, and Ab16 (Figures 1K, 1L, and S2), which are thought to
be produced by sequential cleavage of APP by b- and then(H) PSEN1 and APP V717I mutant neurons exhibit a relative increase in Ab42 comp
from three independent cultures. Error bars, SD; **p < 0.01.
(I) Comparing ratios of Ab40 to the sum of Ab38 and Ab42 at day 80, as an indica
mutants nor increased APP dosage affects APP-C99 cleavage. By contrast, AP
processed to both Ab42 and Ab38. Error bars, SD.
(J) PSEN1 mutant neurons have reduced Ab38:Ab42 ratios, in contrast with all o
bars, SD; **p < 0.01.
(K) Proposed alternative processing pathway of APP in the presence of g-secre
epsilon cleavage followed by a-secretase to generate Ab14/15/16 and AICD.
(L) Percentage of total Ab peptides that are generated from the proposed alter
quantified by IP-MALDI. PSEN1mutant neurons significantly increase the percen
with control and APP V717I neurons. Error bars, SD; **p < 0.01.
(M) Percentage of total Ab peptides that is Ab40 as an indicator of processivity. P
compared with control and APP V717I neurons. Error bars, SD; **p < 0.01.a-secretase in the context of reduced g-secretase processivity
(Portelius et al., 2011). This was accompanied by a reduction
in Ab40, reflecting the shift in production to shorter Ab forms (Fig-
ure 1M), indicating that these hypomorphic PSEN1 mutations
reduce g-secretase’s carboxypeptidase activity.
Increased APPGene Dosage and APP V717I Specifically
Increase Neuronal Tau Protein Levels
Intracellular levels of total and phosphorylated tau were
increased in APP V717I and APPdup neurons, compared with
controls (Figures 2A, 2C–2E, and S3A; n = 2 independent induc-
tions from each iPSC line). The changes in tau protein levels did
not reflect an increase in the relative numbers of neurons car-
rying APP duplications or mutations, assessed by the levels of
the neuron-specific b3-tubulin protein (Figure 2B). Neurons
from two different PSEN1 mutations (Y115C and intron 4) did
not exhibit increased total or phosphorylated tau levels,
compared to controls (Figures 2A, 2C–2E, and S3A). Thus, intra-
cellular tau levels do not correlate with the extracellular
Ab40:Ab42 ratio, as PSEN1mutant neurons exhibited a compa-
rable ratio to APP V717I neurons (Figures 1G and 1H). MAPT
transcription was assessed by RT-PCR, demonstrating no differ-
ence in mRNA expression between neurons of each genotype
(Figure S3B) and suggesting that the increase in tau protein
observed in APP V717I and APPdup neurons is post-transcrip-
tional and a result of altered tau proteostasis.
Pharmacological Manipulation of APP Processing
Regulates Tau Proteostasis in Neurons
As PSEN1 and APP V717I mutant neurons displayed strikingly
different intracellular tau protein levels but comparable levels
of total extracellular Ab and Ab40:Ab42 ratios, we hypothesized
that membrane-bound or intracellular products of APP process-
ing might regulate tau proteostasis. Therefore, we compared the
effects of acute g-secretase or b-secretase inhibition on tau pro-
tein levels in control neurons. As expected, inhibition of either g-
or b-secretase significantly reduced extracellular Ab peptides
(Figure 3A). However, g-secretase inhibition led to an increase
in tau and a marked accumulation of APP-C83/C99. Tau levels
were decreased by b-secretase inhibition (Figure 3B), a treat-
ment that reduces APP-C99 generation. These data indicate a
link between APP processing and tau proteostasis that is regu-
lated by g- and b-secretase activity, independent of extracellular
Ab38, Ab40, and Ab42.ared to Ab40 at day 80, whereas Ts21 andAPP (dup) do not. All data produced
tor of ε-cleavage and processing pathway choice, reveals that neither PSEN1
P V717I mutants significantly bias the ε-cleavage APP-C99 to Ab48, which is
ther genotypes analyzed, suggesting reduced g-secretase processivity. Error
tase inhibitors. APP can be sequentially cleaved by b- and then g-secretase
native pathway (K; Ab14/15/16) as an indicator of processivity, detected and
tage of Ab peptides made up of the sum of Ab1-14, 1-15, and 1-16, compared
SEN1mutant neurons significantly decrease the percentage of Ab40 peptides,
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Figure 2. Increased APP Copy Number and
the V717I Mutation Lead to Increases in
Intracellular Tau Protein Levels, whereas
PSEN1 Mutations Do Not
(A) Total tau levels are increased in APP (dup) and
APP V717I neurons (90 days post-neural induction)
but are not altered in PSEN1 mutants.
(B) Altered tau levels are not accompanied by
changes in neuronal number or mass, assessed by
b3-tubulin levels.
(C) Tau phosphorylation at S202/T205, S396, and
S404 is increased in APP (dup) and APP V717I
neurons, but not PSEN1 mutants, compared to
controls (AT8 and pS396 share actin loading
control; for clarity this appears beneath both
western blots).
(D and E) Quantification of the data presented in
(A), (C), and Figure S3 demonstrating that PSEN1
mutants do not exhibit increases in tau expression
or phosphorylation by western blot analysis. Error
bars, SEM.We compared the effects of the g-secretase inhibitor (GSI)
DAPT with the imidazole-based g-secretase modulator E2012
(GSM) on Ts21 neurons, which exhibit increased tau protein
levels and phosphorylation compared with euploid controls,
providing a sensitive background on which to detect changes
in tau protein. Ts21 neurons treated with DAPT over a 30-day
period exhibited a dose-dependent increase in tau protein levels,
accompanied by corresponding increases in APP-C83/C99 (Fig-
ures 3C and 3E). However, g-secretase modulation resulted in a
dose-dependent decrease in tau protein levels in Ts21 neurons
but did not increase APP-C83/C99 (Figures 3D and 3E).
g-Secretase Modulation Reduces Intracellular Tau
in fAD Neurons
We investigated the effect of manipulating g-secretase activity
on tau proteostasis in different genetic forms of AD. To do so,
we compared the effects of g-secretase inhibition and modula-
tion on APP processing, Ab peptide production, and tau protein
levels in Ts21, PSEN1, and APP V717I neurons, representing AD
initiation due to increased APP copy number, reduced g-secre-
tase carboxypeptidase processivity, and altered ε-cleavage of
APP, respectively.
Inhibition of g-secretase with DAPT significantly reduced the
production of extracellular Ab38, Ab40, and Ab42 in neurons of
all genotypes (Figures4AandS4A–S4C; n=2 independent exper-
iments for eachgenotype).Moreover, IP-MALDI analysis of extra-
cellular DAPT-treated samples revealed a loss of all longer Ab
peptides and a significant increase in Ab14, 15, and 16 (Fig-
ure S4E). By contrast, E2012 reduced the absolute amount of
Ab40 and Ab42 in all genotypes assessed and resulted in a
marked increase of Ab37 and Ab38 (Figures S4A–S4C and S4F),
causing increased Ab40/Ab42 and Ab38/Ab42 ratios for E2012-
treated neurons, compared to vehicle controls (Figures 4B and
4C). Notably, E2012 treatment increased Ab40/Ab42 and Ab38/692 Cell Reports 11, 689–696, May 5, 2015 ª2015 The AuthorsAb42 ratios in PSEN1 mutant neurons,
demonstrating that GSMs can act on
neurons carrying PSEN1 mutations. Themagnitude of this effect was dependent on the nature of the mu-
tation, with PSEN1 intron 4 mutations being least responsive to
g-secretasemodulationbyE2012 (Figures 4A–4DandS4A–S4C).
In agreement with our analyses of control and Ts21 neurons,
DAPT increased total tau levels and APP-C83/99 in neurons of
all genotypes (Figures 4E, 4F, and S4). This was accompanied
by increases in site-specific phosphorylation of tau (pS202/
T205 [AT8], pS396, and pS404; Figures 4E and S4E). E2012
significantly reduced tau protein levels and phosphorylation in
neurons of each genotype, with the exception of PSEN1 intron
4 (Figures 4E and S4G). Ts21 neurons, which displayed the
most marked changes in APP processing in response to
E2012, similarly had the largest increase in both tau protein
expression and phosphorylation (Figures 4E and S4G). Given
that manipulating g-secretase could affect neurogenesis and
neuronal differentiation via Notch signaling, we measured levels
of neuron-specific b3-tubulin in neurons of all genotypes
following treatment with GSI and GSM (Figure 4F). Neither
drug treatment had any effect on b3-tubulin levels (Figure 4F)
and thus did not affect neuronal number or mass.
DISCUSSION
To investigate the relationship between APPmetabolism and tau
protein levels and phosphorylation, we have utilized human-
stem-cell-derived excitatory cortical neurons from representa-
tive genetic forms of AD with mutations in either APP or
PSEN1 that are predicted to affect APP metabolism. In addition
to identifying different classes of altered APP processing and Ab
peptide production under physiological conditions in human
forebrain neurons with different genetic forms of AD, we identi-
fied regulation of tau proteostasis by metabolism of APP.
Marked increases in tau protein levels were observed in genetic
forms of AD that changed APP dosage or affected the
Figure 3. g-Secretase Processing of APP Is Coupled to Tau Proteostasis
(A) Multiplexed ELISA quantification of extracellular Ab peptides from healthy control neurons following treatment with the g-secretase inhibitor, DAPT (GSI),
shows significant reduction in the production of Ab38, Ab40, and Ab42, compared to vehicle controls (Ctrl). Similarly, the b-secretase inhibitor LY2886721 (BSI)
significantly reduces extracellular Ab. Neurons treated between days 64 and 70 with the indicated compounds at a final concentration of 1 mM. Error bars, SD.
n = 3 cultures for each treatment group; **p < 0.01.
(B) Immunoblot detection of APP-C83/99 peptides, total tau, and b3-tubulin extracted from healthy control neurons following treatment with DMSO (Ctrl), BSI,
and GSI. BSI treatment reduces tau protein levels with no detectable changes in APP-C83/99, compared to DMSO-treated controls. By contrast, GSI treatment
markedly increases both APP-C83/99 and tau in control neurons.
(C–E) Ts21 neurons treated with DAPT (GSI) for a 30-day period between days 60 and 90 post-induction exhibit a dose-dependent increase in both APP-C83/99
and tau protein. Treatment with the g-secretase modulator E2012 (GSM) reduced tau levels in Ts21 neurons in a dose-dependent manner, with no detectable
changes in APP-C83/C99.ε-cleavage site of APP. Furthermore, pharmacological manipula-
tion of APP metabolism changed tau protein levels in human
forebrain neurons in a dose-dependent manner. These findings
point to a potentially important pathogenic mechanism in AD,
linking APP metabolism to tau protein levels. The pathological
significance of tau protein levels is clear from the small number
of identified individuals with frontotemporal dementia and
MAPT duplications (Hooli et al., 2014; Rovelet-Lecrux et al.,
2010).
Recent in vitro studies of AD employing overexpression of
transgenes encoding mutant forms of PSEN1 and APP in human
neurons or iPSC-derivedAPP V717I neurons have demonstrated
an association between APP processing and tau pathology that
is dependent on extracellular Ab peptides (Choi et al., 2014; Mur-
atore et al., 2014). Consistent with previous studies, we found
that neurons from all fAD lines in this study led to an increase
in extracellular Ab42. However, only APP duplication, Ts21,
andAPP V717I resulted in increased tau protein levels and phos-
phorylation. Elevated tau protein levels were not due to an
increase in MAPT mRNA expression, suggesting a post-tran-
scriptional mechanism.
Given the similarity in extracellular total Ab levels and specif-
ically Ab42, among different PSEN1 and APP mutant neurons,we hypothesized that the increase in intracellular tau protein
seen in a subset of genetic forms of ADmay be regulated by fac-
tors in addition to extracellular Ab. As the three genotypes in
which increased tau occurs either affect total APP levels (Ts21;
APP duplication) or the initial ε-cleavage of APP by g-secretase
(APP V717I), our studies focused on the initial intracellular pro-
cessing of APP to generate APP-C83/99. Therefore, we
compared the effects of b-secretase and g-secretase inhibition
on APP processing and tau proteostasis in human cortical neu-
rons. Both compounds greatly reduce extracellular Ab peptide
production but at different stages of the APP-processing
pathway (De Strooper, 2010). b-secretase inhibition prevents
generation of APP-C99 from full-length APP, whereas g-secre-
tase inhibition blocks the proteolysis of APP-C83/99, resulting
in accumulation of APP-C83/99. In support of a role for APP
metabolism and APP-C83/99 in regulating tau levels, we found
that g-secretase inhibition increased intracellular tau protein
levels, whereas b-secretase inhibition reduced intracellular tau
protein.
The strategy of g-secretase modulation reduced tau protein in
different genetic forms of AD, suggesting that this approach to
reducing tau levels may be a useful therapeutic strategy in
different forms of Alzheimer’s disease. The reduction in tauCell Reports 11, 689–696, May 5, 2015 ª2015 The Authors 693
Figure 4. Manipulation of g-Secretase Activity Alters Ab Peptide Production, Tau Expression, and Phosphorylation Status in Genetic Forms
of AD
(A) DAPT (GSI) prevents the production of Ab38, Ab40, and Ab42 observed in DMSO-treated controls (Ctrl). In contrast, E2012 (GSM) reduces total Ab peptide
production by approximately one third. All compounds used at 1 mM and extracellular media analyzed at day 80 post-neural induction, after 20 days of drug
treatment. Error bars, SD. Neurons of each genotype are as marked; n = 3 cultures for each treatment group; **p < 0.01.
(B–D) Changes in relative Ab peptide production in response to each compound are reflected in the ratios between the different Ab species. E2012 (GSM) has
particularly marked effects in reducing the concentration of Ab42 relative to Ab40 (B) and in increasing the concentration of Ab38 relative to Ab42 (C). Error bars,
SD; **p < 0.01.
(E) Western blots performed on soluble protein extracts of neurons following treatment with the indicated compounds. Protein extraction performed at day 90
post-neural induction, after 30 days of drug treatment. DAPT treatment (GSI) increases both total and phosphorylated tau expression in themajority of genotypes,
assessed at multiple epitopes. By contrast, E2012 (GSM) reduces total tau expression and its phosphorylation in all genotypes assayed, with particularly
pronounced effects in Ts21 neurons. Error bars, SD; n = 2 for each treatment group; representative western blots shown, with additional data in Figure S4.
(F) GSI with DAPT increased APP-C83/99 in neurons of all genotypes, with differing efficacy in some PSEN1 mutants, whereas GSM (E2012) had no effect on
APP-C83/99. Drug treatments had no effect on neuronal number, as reflected in the amount of neuron-specific b3-tubulin.protein by g-secretasemodulation with E2012 had differential ef-
fects depending on the specific mutation, with the degree of tau
reduction correlated with the magnitude of the change in APP
processing in each genotype. For example, E2012 had the
most-pronounced effects on APP processing and tau levels in
Ts21/Down syndrome neurons and the least effects on both
APP processing and tau protein levels in PSEN1 intron 4 neu-
rons. Finally, g-secretase modulation also reduced tau protein
levels in healthy controls, indicating that the link between APP
metabolism and tau proteostasis is a feature of neuronal biology
in health and disease.
Overall, our data support a link between APP metabolism and
tau proteostasis that ismediated by b- and g-secretase. The lack
of changes in tau protein inPSEN1mutant neurons indicates that
a simple lack of carboxypeptidase processivity does not lead to
altered tau proteostasis. Instead, the data reported here suggest
the changes in tau levels are related to altered ε-cleavage of APP
by endopeptidase activity of g-secretase and point to a possible
role for APP-C99 in regulating tau proteostasis. A key question
for further study is how intracellular metabolism of APP may
input into controlling tau proteostasis, given the potential impor-
tance of this pathway for AD progression.694 Cell Reports 11, 689–696, May 5, 2015 ª2015 The AuthorsEXPERIMENTAL PROCEDURES
Generation of Familial Alzheimer’s Disease iPSCs and Cerebral
Cortex Neurons
PSEN1 Y115C, M146I, intron 4, and APP V717I mutant fibroblasts were
sourced as described (Wray et al., 2012). Fibroblasts were reprogrammed at
the Cambridge Biomedical Centre using the standard four-factor method,
delivered by lentiviruses (Takahashi et al., 2007). Each mutation was
sequenced in reprogrammed clones, and pluripotency was determined by dif-
ferentiation to each germ layer from embryoid bodies (Figure S1). Healthy con-
trol cell lines were NDC (Israel et al., 2012), NAS6 (Devine et al., 2011), and the
H9 ES (WiCell Research Institute); additional disease lines were APP duplica-
tion (Israel et al., 2012) and Ts21 iPSCs (Park et al., 2008). Pluripotent cells
were cultured by standardmethods (see Supplemental Information for details).
Directed differentiation of hESCs and iPSCs to cerebral cortex was carried
out as described, with minor modifications (Shi et al., 2012b, c). For drug treat-
ment, all compounds were dissolved in DMSO at the concentrations noted,
andDMSOwas the vehicle control in all experiments. Compoundswere added
every 48 hr during treatment period: g-secretase inhibitor, DAPT (Sigma); g-
secretase modulator, E2012 (ChemExpress); and b-secretase inhibitor
LY2886721 (Selleck).
Immunocytochemistry and Imaging
Fixed and immunostained cultures were imaged on an Olympus FV1000 in-
verted confocal microscope (see Supplemental Information for details). For
optical clearing, fixed cultures were processed according to the method
described (Yang et al., 2014).
Protein Analysis
Quantification of Ab42, Ab40, and Ab38 were carried out with multiplexed
MesoScale Discovery assay kits on a Quickplex SQ120 instrument (Meso-
Scale Discovery) using 25 ml of cell culture supernatant. All statistical compar-
isons were between the entire set of controls samples and all samples of each
genotype, using Student’s t test with the Bonferroni correction for multiple
testing. Three independent cultures of neurons derived from each clone
were used for all measurements, except where noted. Cellular protein extrac-
tion and western blot analysis were carried out as described (Supplemental
Information).
IP-MALDI Analysis of Ab Peptides
IP of cell media was performed using a KingFisher magnetic particle processor
(Thermo Scientific) as described (Portelius et al., 2007). See Supplemental In-
formation for further details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.03.068.
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